SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
